Randomized, multifactorial, double-blind, parallel-group, dose-ranging study of the efficacy and safety of rituximab (MabThera/Rituxan) in combination with methotrexate in patients with active rheumatoid arthritis

Trial Profile

Randomized, multifactorial, double-blind, parallel-group, dose-ranging study of the efficacy and safety of rituximab (MabThera/Rituxan) in combination with methotrexate in patients with active rheumatoid arthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Rituximab (Primary) ; Corticosteroids; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 23 Feb 2010 Additional locations identified as reported by Roche website.
    • 27 Sep 2008 Planned end date changed to 1 Jun 2012.
    • 27 Sep 2008 Updated official title.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top